Early tocilizumab and outcomes in acute necrotizing encephalopathy
Developmental Medicine & Child Neurology · 19.08.2026
DOI: 10.1111/dmcn.70454 ↗Kurz gefasst
Fachartikel in der Zeitschrift Developmental Medicine & Child Neurology, online erschienen am 19.08.2026. Verfasst von Velda X Han und 14 weiteren Autor:innen. Beteiligte Einrichtung: Khoo-Teck Puat-National Children's Medical Institute, National University Health System, Singapore, Singapore. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aim
To evaluate the timing and safety of tocilizumab in acute necrotizing encephalopathy (ANE).
Method
This was a multicentre retrospective study evaluating outcomes (modified Rankin Scale [mRS]) in children with ANE treated with tocilizumab. A logistic regression model determined a cut‐off for outcomes (binary good [mRS 0–2] vs poor [mRS 3–5]) according to day of tocilizumab administration, enabling a dichotomy of ‘early’ and ‘late’ treatment groups. Expected outcomes according to ANE severity score (ANE‐SS) in early‐treatment and late‐treatment groups were compared against reference data (conventional therapy, no tocilizumab) for outcomes according to risk category (medium risk: ANE‐SS score 2–4; high risk: ANE‐SS score ≥5).
Results
From 2018 to 2023, 63 children (mean age 6 years 0 months [range: 8 months–15 years 4 months]; 33 males, 30 females) were treated with tocilizumab, alongside corticosteroids in all and intravenous immunoglobulin in 33 (52.4%). Logistic regression defined an optimal treatment window of ≤3.3 days. Compared to the reference data, early tocilizumab (≤ 72 hours after onset, n = 49) was associated with good outcomes in both high‐risk (OR = 11.43, 95% confidence interval [CI] = 1.64–127.4, p = 0.01) and medium‐risk (OR = 12.80, 95% CI = 2.15–67.8; p = 0.006) ANE‐SS categories. No tocilizumab‐related adverse events were reported.
Interpretation
Early tocilizumab treatment was associated with improved outcomes in severe ANE, with no adverse events, compared to conventional therapy alone.
Autor:innen und Institutionen
- Khoo-Teck Puat-National Children's Medical Institute, National University Health System, Singapore, Singapore.
- Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
- The Children's Hospital at Westmead Clinical School, Faculty of Medicine and Healthy, University of Sydney, Sydney, New South Wales, Australia.
- Dhulikhel Hospital, Kathmandu University Hospital, Dhulikhel, Nepal.
- Children's Neurosciences, Evelina London Children's Hospital at Guy's and St Thomas' NHS Foundation Trust, London, UK.
- Paediatric Neurology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
ORCID-Profile: Velda X Han, Prithuja Poudyal, Vanessa Lee, Arushi Gahlot Saini, Shekeeb S Mohammad, Sekhar C Pillai, Gouri Rao Passi, Naveen Sankhyan, Ahmad Rithauddin Mohamed, Lokesh Lingappa, Hiroshi Sakuma, Russell C Dale, Ming Lim, Terrence Thomas
Zitieren
APA
Han, V. X., Poudyal, P., Lee, V., Saini, A. G., Mohammad, S. S., Pillai, S. C., Passi, G. R., Sankhyan, N., Mohamed, A. R., Lingappa, L., Sakuma, H., Dale, R. C., Lim, M., Thomas, T., & International ANE Study Group (2026). Early tocilizumab and outcomes in acute necrotizing encephalopathy. Developmental Medicine & Child Neurology. https://doi.org/10.1111/dmcn.70454
Vancouver
Han VX, Poudyal P, Lee V, Saini AG, Mohammad SS, Pillai SC, et al. Early tocilizumab and outcomes in acute necrotizing encephalopathy. Developmental Medicine & Child Neurology. 2026. doi:10.1111/dmcn.70454
BibTeX
@article{Han2026,
author = {Han, Velda X and Poudyal, Prithuja and Lee, Vanessa and Saini, Arushi Gahlot and Mohammad, Shekeeb S and Pillai, Sekhar C and Passi, Gouri Rao and Sankhyan, Naveen and Mohamed, Ahmad Rithauddin and Lingappa, Lokesh and Sakuma, Hiroshi and Dale, Russell C and Lim, Ming and Thomas, Terrence and International ANE Study Group, International ANE Study Group},
title = {Early tocilizumab and outcomes in acute necrotizing encephalopathy},
journal = {Developmental Medicine & Child Neurology},
year = {2026},
doi = {10.1111/dmcn.70454}
}
EUVIMED